Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.verified

GRCL

Price:

$10.25

Market Cap:

$7.17B

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-...[Read more]

Industry

Biotechnology

IPO Date

2021-01-08

Stock Exchange

NASDAQ

Ticker

GRCL

The PE Ratio as of April 2024 (TTM) for Gracell Biotechnologies Inc. (GRCL) is -10.57

According to Gracell Biotechnologies Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.57. This represents a change of 219.90% compared to the average of -3.30 of the last 4 quarters.

Gracell Biotechnologies Inc. (GRCL) Historical PE Ratio (quarterly & annually)

How has GRCL PE Ratio performed in the past?

The mean historical PE Ratio of Gracell Biotechnologies Inc. over the last ten years is -28.98. The current -10.57 PE Ratio has changed 3.55% with respect to the historical average. Over the past ten years (40 quarters), GRCL's PE Ratio was at its highest in in the March 2023 quarter at -1.43. The PE Ratio was at its lowest in in the September 2020 quarter at -55.16.

Quarterly (TTM)
Annual

Average

-28.98

Median

-26.14

Minimum

-56.14

Maximum

-2.81

Gracell Biotechnologies Inc. (GRCL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Gracell Biotechnologies Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 108.08%

Maximum Annual PE Ratio = -2.81

Minimum Annual Increase = -90.01%

Minimum Annual PE Ratio = -56.14

Quarterly (TTM)
Annual
YearPE RatioChange
2022-2.81-48.35%
2021-5.43-90.01%
2020-54.38108.08%
2019-26.14-53.45%

Gracell Biotechnologies Inc. (GRCL) Average PE Ratio

How has GRCL PE Ratio performed in the past?

The current PE Ratio of Gracell Biotechnologies Inc. (GRCL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-20.87

5-year avg

-28.98

10-year avg

-28.98

Gracell Biotechnologies Inc. (GRCL) PE Ratio vs. Peers

How is GRCL’s PE Ratio compared to its peers?

Gracell Biotechnologies Inc.’s PE Ratio is less than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-2.34), less than Design Therapeutics, Inc. (-3.01), less than Erasca, Inc. (-2.34), less than NextCure, Inc. (-0.65), less than CytomX Therapeutics, Inc. (61.88), less than Neoleukin Therapeutics, Inc. (-0.98), less than Spero Therapeutics, Inc. (3.17), less than Assembly Biosciences, Inc. (-1.22), less than Terns Pharmaceuticals, Inc. (-3.81), less than Amylyx Pharmaceuticals, Inc. (2.57), less than Acumen Pharmaceuticals, Inc. (-3.64), less than Inozyme Pharma, Inc. (-3.88), less than X4 Pharmaceuticals, Inc. (-1.93), less than Bolt Biotherapeutics, Inc. (-0.67), less than Coherus BioSciences, Inc. (-0.95), less than Icosavax, Inc. (-8.27), less than Day One Biopharmaceuticals, Inc. (-7.28), less than Decibel Therapeutics, Inc. (-1.94), greater than Blueprint Medicines Corporation (-11.08),

Build a custom stock screener for Gracell Biotechnologies Inc. (GRCL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gracell Biotechnologies Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gracell Biotechnologies Inc. (GRCL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gracell Biotechnologies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Gracell Biotechnologies Inc.'s PE Ratio?

How is the PE Ratio calculated for Gracell Biotechnologies Inc. (GRCL)?

What is the highest PE Ratio for Gracell Biotechnologies Inc. (GRCL)?

What is the 3-year average PE Ratio for Gracell Biotechnologies Inc. (GRCL)?

What is the 5-year average PE Ratio for Gracell Biotechnologies Inc. (GRCL)?

How does the current PE Ratio for Gracell Biotechnologies Inc. (GRCL) compare to its historical average?